WilmerHale Counsels Catabasis in $42M Public Offering

• 7.12.2018

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the closing of a $42 million underwritten public offering of common stock and warrant units on June 22, 2018. Oppenheimer & Co. Inc. is acting as the sole underwriter for the offering. Catabasis intends to use the net proceeds for the planned Phase 3 clinical trial of edasalonexent for the treatment of Duchenne muscular dystrophy, as well as for working capital and other corporate purposes.

The WilmerHale team representing Catabasis is led by Rosemary Reilly and includes Jeffries Oliver-Li and Libby Ragan.

Read Catabasis’ press release about the offering.